{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:46:20Z","timestamp":1791751580154,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102660","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:10:21Z","timestamp":1788390621000},"page":"102660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["EVOLUTE: Enfortumab Vedotin in OLder patients with locally advanced\/metastatic UroThElial carcinoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-4120","authenticated-orcid":false,"given":"Ilg\u0131n","family":"Akb\u0131y\u0131k","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-0069","authenticated-orcid":false,"given":"Mathilde","family":"Cabart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-8693","authenticated-orcid":false,"given":"Arnaud","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Aptecar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-214X","authenticated-orcid":false,"given":"Mathilde","family":"Cancel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1658-2183","authenticated-orcid":false,"given":"Th\u00e9ophile","family":"Bertail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6251-622X","authenticated-orcid":false,"given":"Cedric","family":"Pobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1739","authenticated-orcid":false,"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Naoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0263-7094","authenticated-orcid":false,"given":"Maxime","family":"Fr\u00e9laut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clgc.2026.102660_bib0001","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA"},{"issue":"17","key":"10.1016\/j.clgc.2026.102660_bib0003","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clgc.2026.102660_bib0004","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102660_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jgo.2016.11.001","article-title":"Enrollment of older adults on oncology trials: an FDA perspective","volume":"8","author":"Singh","year":"2017","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102660_bib0006","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2026.102660_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102660_bib0008","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1634\/theoncologist.2019-0166","article-title":"Inclusion of older patients with cancer in clinical trials: the SAGE prospective multicenter cohort Survey","volume":"24","author":"Canoui-Poitrine","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.clgc.2026.102660_bib0009","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102660_bib0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"10314","key":"10.1016\/j.clgc.2026.102660_bib0011","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clgc.2026.102660_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103657","article-title":"Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO\/SIOG Cancer in the Elderly Working Group","volume":"9","author":"Loh","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.clgc.2026.102660_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2026.102660_bib0014","unstructured":"National Cancer Institute common terminology criteria for adverse events, version 5.0. Available from https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf, 2017. Accessed September 16, 2025."},{"issue":"16","key":"10.1016\/j.clgc.2026.102660_bib0015","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression","volume":"21","author":"Heinze","year":"2002","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.clgc.2026.102660_bib0016","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.clgc.2026.102660_bib0017","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2026.102660_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71284","article-title":"Treatment-related adverse events and associated outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: analysis of the UNITE study","volume":"14","author":"Nizam","year":"2025","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.clgc.2026.102660_bib0019","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.21873\/anticanres.17161","article-title":"Enfortumab vedotin for elderly advanced urothelial carcinoma patients or those with a poor performance status","volume":"44","author":"Furubayashi","year":"2024","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2026.102660_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.102183","article-title":"Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: a multicenter retrospective study","volume":"16","author":"Shindo","year":"2025","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102660_bib0021","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.21873\/anticanres.17803","article-title":"Real-world outcomes of enfortumab vedotin in elderly patients with metastatic urothelial carcinoma","volume":"45","author":"Nishio","year":"2025","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102660_bib0022","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamaoncol.2025.4566","article-title":"Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer","volume":"12","author":"Chow","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2026.102660_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.734","article-title":"Real world toxicity profile of enfortumab vedotin (EV) with or without pembrolizumab (P) in ultra elderly urothelial carcinoma (UC) patients (pts)","volume":"43","author":"Mar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102660_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70479","article-title":"Real-life impact of enfortumab vedotin or chemotherapy in the sequential treatment of advanced urothelial carcinoma: the ARON-2 retrospective experience","volume":"14","author":"Rizzo","year":"2025","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.clgc.2026.102660_bib0025","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102660_bib0026","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/iju.15542","article-title":"Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastases","volume":"31","author":"Yoshida","year":"2024","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102660_bib0027","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/j.clgc.2020.01.002","article-title":"A California Cancer Registry analysis of urothelial and non-urothelial bladder cancer subtypes: epidemiology, treatment, and survival","volume":"18","author":"Martin","year":"2020","journal-title":"Clin Genitourin Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:03:49Z","timestamp":1791749029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S1558767326001606"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102660","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EVOLUTE: Enfortumab Vedotin in OLder patients with locally advanced\/metastatic UroThElial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102660"}}